Active Surveillance for Intermediate-risk Prostate Cancer Daniel E Spratt Stacy Loeb, MD Pawel Rajwa Michael Leapman sciencedirect.com/science/articl…

Many claimed that it would be impossible to randomize patients between RT+ADT or RP in cT3N0M0 #prostatecancer . But we are well underway. Kudos to #SPCG15 and Olof Akre pubmed.ncbi.nlm.nih.gov/35813256/ Antti Rannikko Urological research unit - Rigshospitalet

Current Issue: Vasectomy and Risk of Prostate Cancer: A Systematic Review and Meta-analysis

buff.ly/3obG8vi

Pawel Rajwa Eric Barret Charles Dariane Gaelle Fiard MATHIEU Romain Roubaud Guilhem Paul Sargos Morgan Roupret Ploussard Guillaume

#prostatecancer #urology #openscience #openaccess

It has been a wonderful journey through Urologic Oncology fellowship 🇦🇹. Thank you to my mentor Shahrokh F. Shariat for guiding me. Thanks to my family and friends for always supporting me. Looking forward to going back to مستشفى الملك فهد التخصصي بالدمام 🇸🇦

📸 Mamy to na co długo czekaliśmy: Polak w Barcelonie i to jaki! 🇵🇱 🔵🔴

New Research: Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial thelancet.com/journals/lanin… (1/2)

In man with BRCA2 mut prostate cancer is the most common maligancy. Any data on cancer type responsible for the highest number of deaths in this population? #EAU22 EAU YAU Prostate Cancer Working Group Matt Cooperberg Ploussard Guillaume Giorgio Gandaglia Juan Gómez Rivas Roderick v/d Bergh

Proud to be part of a fantastic European Association of Urology (EAU) team EAU YAU Prostate Cancer Working Group group busy working on future studies in #Pca #EAU22 Giorgio Gandaglia Roderick v/d Bergh Giancarlo Marra Claudia Kesch Jonathan Olivier Paweł Rajwa Peter Ka-Fung CHIU European Society of Residents in Urology Juan Gómez Rivas

NEW IMPACT FACTORS in #Urology 2022

What an honor to be the visiting professor MedUni Wien Urologic Oncology Research MedUni Vienna with the amazing Shahrokh F. Shariat and colleagues, residents and fellows. Such an inspiring department. Thanks to all who made this such a special trip!

It was a great honor to have Prof. Sia Daneshmand, M.D. as visiting professor MedUni Wien. We had two great days of meetings, surgeries, and lectures! Shahrokh F. Shariat Urologic Oncology Research MedUni Vienna USC Urology

Prostate-specific membrane antigen positron emission tomography (PSMA-PET) is a promising imaging method for detecting clinically significant prostate cancer and seems to have additional value to magnetic resonance imaging (MRI) for detection.
sciencedirect.com/science/articl…

My must see #ASCO22 on #ProstateCancer #Chicago
ASCO OncoAlert ASCOPres Simon Chowdhury Neeraj Agarwal @azadOncology Daniel Castellano Enrique Grande Tatiana Prowell, MD Alicia Morgans, MD, MPH @drchoueiri Sumanta Pal UroToday.com

Vasectomy and Risk of Prostate Cancer: A Systematic Review and Meta-analysis by the PCa committee of ⁦AFU⁩ sciencedirect.com/science/articl…

Dziękuję FNP.org.pl za prestiżowe wyróżnienie! Ogromnym zaszczytem jest moja obecność wsród topowych młodych polskich naukowców. 🇵🇱👍

Current Issue: Comparative Outcomes of Primary Versus Recurrent High-risk Non–muscle-invasive and Primary Versus Secondary Muscle-invasive BC After Radical Cystectomy: Results from a Retrospective Multicenter Study

buff.ly/3KxchpU

#urology #openaccess #openscience

Systemic therapy decreases the accuracy of PSMA-PET in patients treated for oligometastatic prostate cancer Shahrokh F. Shariat sciencedirect.com/science/articl…

What is the evidence of systemic therapies (alone or in combination with MDT) in oligometastatic #mHSPC ? Presentation by Mary-Ellen Taplin, MD Dana-Farber. #APCCC22 written coverage by Christopher Wallis University of Toronto on UroToday > bit.ly/3MKuiCP APCCC22